DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Enoxaparin Versus Unfractionated Heparin in PCI

Information source: Triemli Hospital
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Coronary Artery Disease

Intervention: Enoxaparin i.v. (Drug); unfractionated heparin (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Triemli Hospital

Official(s) and/or principal investigator(s):
osmund bertel, MD, Principal Investigator, Affiliation: Division of Cardiology Triemli Hospital Zurich

Summary

Enoxaparin 0. 75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Clinical Details

Official title: Enoxaparin Versus Unfractionated Heparin in PCI

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Quadruple endpoint: death, MI, urgent TVR, major bleeding

Secondary outcome: major bleeding, minor bleeding, thrombocytopenia

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- PCI for stable ischemia or ACS

Exclusion Criteria:

- Cardiogenic shock,

- Pretreatment with study drugs,

- Lack of informed consent

Locations and Contacts

Division of Cardiology Triemli Hospital Zurich, Zurich 8063, Switzerland
Additional Information

Starting date: September 2003
Last updated: February 23, 2007

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017